PVLA
Palvella
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About PVLA
Palvella Therapeutics, Inc.
A clinical stage biotechnology company focused on discovering and developing innovative therapies based on Anticalin protein for the treatment of respiratory and cancer diseases
125 Strafford Ave, Suite 360, Wayne, Pennsylvania 19087
--
Palvella Therapeutics, Inc., was incorporated under the laws of Nevada on May 24, 2013. The company is a biotechnology company that has historically discovered and developed Anticalin protein-based drugs that target proven disease pathways in unique and transformative ways. On March 27, 2024, the Company implemented measures to maximize its ability to collect potential milestones from its clinical pipeline of collaborative drug candidates and maintain its ability to consider other strategic options. The company's clinical pipeline includes immuno-oncology or IO bispecific drugs in collaboration with collaborators, including S095012 (also known as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also known as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also known as PRS-342) targeting GPC3 and 4-1BB. Anticalin protein is proprietary to the company and is a new class of therapies that have been clinically validated through partnerships with leading pharmaceutical companies.
Company Financials
EPS
PVLA has released its 2025 Q1 earnings. EPS was reported at -0.74, versus the expected -1.00, beating expectations. The chart below visualizes how PVLA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
